The HELIOS-study: effect of roflumilast in COPD patients treated with tiotropium. A 24-week, double-blind study with 500microg roflumilast once daily versus placebo.

Trial Profile

The HELIOS-study: effect of roflumilast in COPD patients treated with tiotropium. A 24-week, double-blind study with 500microg roflumilast once daily versus placebo.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms HELIOS
  • Sponsors Takeda
  • Most Recent Events

    • 20 May 2012 Results reported at the 108th International Conference of the American Thoracic Society.
    • 07 May 2012 Company added in the association field and additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 18 May 2010 Body composition results have been presented at the 106th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top